Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Jazyk angličtina Země Irsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27816693
DOI
10.1016/j.tox.2016.11.002
PII: S0300-483X(16)30261-X
Knihovny.cz E-zdroje
- Klíčová slova
- Anthracyclines, Cardioprotection, Daunorubicin, Doxorubicin, Molsidomine, Morpholinosydnoimine, Nitric oxide, SIN-1,
- MeSH
- antracykliny toxicita MeSH
- chronická nemoc MeSH
- daunomycin toxicita MeSH
- donory oxidu dusnatého farmakologie MeSH
- doxorubicin toxicita MeSH
- kardiotonika farmakologie MeSH
- kardiotoxicita MeSH
- králíci MeSH
- molsidomin farmakologie MeSH
- nádorové buněčné linie MeSH
- nemoci srdce chemicky indukované prevence a kontrola MeSH
- oxidační stres účinky léků MeSH
- peroxidace lipidů účinky léků MeSH
- proliferace buněk účinky léků MeSH
- protinádorová antibiotika toxicita MeSH
- reaktivní formy kyslíku metabolismus MeSH
- remodelace komor účinky léků MeSH
- srdeční selhání prevence a kontrola MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antracykliny MeSH
- daunomycin MeSH
- donory oxidu dusnatého MeSH
- doxorubicin MeSH
- kardiotonika MeSH
- molsidomin MeSH
- protinádorová antibiotika MeSH
- reaktivní formy kyslíku MeSH
Chronic anthracycline (ANT) cardiotoxicity is a serious complication of cancer chemotherapy. Molsidomine, a NO-releasing drug, has been found cardioprotective in different models of I/R injury and recently in acute high-dose ANT cardiotoxicity. Hence, we examined whether its cardioprotective effects are translatable to chronic ANT cardiotoxicity settings without induction of nitrosative stress and interference with antiproliferative action of ANTs. The effects of molsidomine (0.025 and 0.5mg/kg, i.v.) were studied on the well-established model of chronic ANT cardiotoxicity in rabbits (daunorubicin/DAU/3mg/kg/week for 10 weeks). Molsidomine was unable to significantly attenuate mortality, development of heart failure and morphological damage induced by DAU. Molsidomine did not alter DAU-induced myocardial lipoperoxidation, MnSOD down-regulation, up-regulation of HO-1, IL-6, and molecular markers of cardiac remodeling. Although molsidomine increased 3-nitrotyrosine in the myocardium, this event had no impact on cardiotoxicity development. Using H9c2 myoblasts and isolated cardiomyocytes, it was found that SIN-1 (an active metabolite of molsidomine) induces significant protection against ANT toxicity, but only at high concentrations. In leukemic HL-60 cells, SIN-1 initially augmented ANT cytotoxicity (in low and clinically achievable concentrations), but it protected these cells against ANT in the high concentrations. UHPLC-MS/MS investigation demonstrated that the loss of ANT cytotoxicity after co-incubation of the cells in vitro with high concentrations of SIN-1 is caused by unexpected chemical depletion of DAU molecule. The present study demonstrates that cardioprotective effects of molsidomine are not translatable to clinically relevant chronic form of ANT cardiotoxicity. The augmentation of antineoplastic effects of ANT in low (nM) concentrations may deserve further study.
Citace poskytuje Crossref.org
